EGI
FULC icon

EAM Global Investors’s Fulcrum Therapeutics FULC Stock Holding History

EAM Global Investors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-78,384
Closed -$2.21M – 218
2021
Q3 		$2.21M Buy
+78,384
New +$1.49M 0.52% 83

Other funds holding FULC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

EAM Global Investors's FULC Position: Q4 2021 in Review

EAM Global Investors sold out of Fulcrum Therapeutics (FULC) in Q4 2021, closing a stake of 78,384 shares — an estimated $2.21M sold.

EAM Global Investors first reported a position in FULC in Q3 2021 and held it in 1 quarter. The position peaked at $2.21M in Q3 2021. 110 funds tracked by Wall St. Rank hold FULC as of Q4 2021.

  • EAM Global Investors reported no remaining Fulcrum Therapeutics position as of Q4 2021 after selling out during the quarter.
  • EAM Global Investors sold 78,384 Fulcrum Therapeutics shares in Q4 2021, an estimated $2.21M.
  • EAM Global Investors first reported a position in Fulcrum Therapeutics in Q3 2021 and held it in 1 quarter.
  • EAM Global Investors's Fulcrum Therapeutics position peaked at $2.21M in Q3 2021.
  • 110 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2021.

Based on EAM Global Investors's 13F filing for Q4 2021, filed 11 Feb 2022.